SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
A diagnostic and therapeutic company in La Jolla has recruited Franz Och, scientist and former head of Google Translate, as the company’s chief data scientist.
Illumina Inc. announced that Jeff Huber, senior vice president at Google Inc., has been appointed to its board of directors.
A diagnostics company in San Diego has raised $30 million in Series C financing to help commercialize its new technology for cancer research.
The Food and Drug Administration has warned CareFusion 2200 Inc., a subsidiary of San Diego-based CareFusion Corp., that it failed to satisfactorily investigate and respond to 32 complaints of particulate matter and debris found in certain medical devices
Sequenom Inc., a life sciences company that provides genetic analysis solutions, and Mayo Medical Laboratories, one of the top providers of esoteric laboratory services in the U.S., have announced a license agreement for Sequenom’s noninvasive prenatal testing patents and applications.
NuVasive reported second quarter 2014 revenue of $190.7 million as compared with $165.7 million from the previous year.
La Jolla Pharmaceutical Co., a therapeutics company focused on unmet life-threatening diseases, announced the closing of its underwritten $56.6 million public offering.
PaxVax, Inc., a Redwood City-based vaccine company with manufacturing facilities in San Diego, announced that it has secured up to $62 million in additional funding as part of the acquisition of an oral typhoid vaccine, Vivotif, from Crucell Switzerland AG.
Quidel Corp., a San Diego-based diagnostics company, has received FDA clearance for its molecular diagnostic test, AmpliVue GAS Assay, used for detecting Group A strep.
San Diego-based Cypher Genomics Inc. announced a co-promotion agreement with Illumina Inc. and the selection of Adam Simpson as president and chief operating officer.
DJO Global Inc., the Vista-based maker of orthopedic devices, reporter second quarter net sales of $313.9 million, up 6.5 percent from the like quarter of 2013.
Pfenex Inc., a Sorrento Valley biotech firm specializing in a class of drugs called biosimilars, raised $50 million in its initial public offering July 23, selling 8.33 million shares at $6 per share.
La Jolla Pharmaceutical Co., a developer of therapeutics targeting unmet life-threatening diseases, announced a price of $10.50 per share for a planned underwritten stock offering of 4.8 million shares of common stock.
Illumina Inc. reported revenue of $448 million for the second quarter ending June 29.
La Jolla Pharmaceutical Co., a developer of therapeutics targeting unmet life-threatening diseases, intends to sell shares of common stock in an underwritten offering pursuant to its existing shelf registration statement, the company announced.